Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 7 of 7 for “"Antiplatelet agents"”.
-
Uso do ácido acetilsalicílico na prevenção de doenças cardiovasculares.
… been considered for many years as the standard antiplatelet secondary prevention of vascular diseases, therefore, their effectiveness is independent of sex or age associated diseases such as diabetes or hypertension. Over time, other antiplatelet agents began to be chosen as a substitute for …
-
Retrospective evaluation of the rockall risk scoring system in patients with nonvariceal upper gastrointestinal hemorrhage at a community hospital
… resources utilized and evaluated whether certain antiplatelet agents, anticoagulants, and NSAIDS affected the Rockall scores. The Rockall scoring system identified 21% of patients as having low Rockall scores, with no significant differences in length of stay between risk groups. Our study shows …
-
Evaluating Risk of Delayed Major Bleeding in Critically Ill Trauma Patients
… included: male gender, pre-injury use of the antiplatelet agents aspirin and/or clopidogrel, presence of intracranial bleeding, higher injury severity scores, requirement of massive transfusion, and low pH values. Use of anticoagulant prophylaxis was not associated with delayed major bleeding. …
-
Mechanisms of platelet inhibition by the selective serotonin reuptake inhibitor citalopram
… a pharmacological approach to develop novel antiplatelet agents based on current antidepressants.
-
The Molecular Mechanism of Platelet Activation in Inflammation
… suppressed activation. Additionally, the antiplatelet agents aspirin and cangrelor significantly reduced histone mediated activation by targeting thromboxane A2 and P2Y12 receptor-mediated pathways, respectively. These findings suggest that histones directly disrupt the platelet membranes, …
-
Re-evaluation of the in vitro activity of the protease activated receptor-1 (PAR1) pepducin PZ-128
… of the leading causes of death globally, with antiplatelet agents commonly used for the clinical management of these conditions. Unfortunately, not all patients respond to existing antiplatelet therapies, which can result in vascular event recurrence and death. This has led to the need to …
-
Genotype- versus phenotype-directed personalization of antiplatelet treatment in Koreans with coronary artery disease undergoing coronary stenting
… of patients with HOPR at the baseline. Tailored antiplatelet therapy according to point-of-care genetic and phenotypic testing is feasible and effective in decreasing HOPR after 30 days.